Skip to main navigation Skip to search Skip to main content

Hepatopulmonary syndrome in patients with cystic fibrosis and liver disease

  • Oded Breuer
  • , Eyal Shteyer
  • , Michael Wilschanski
  • , Zeev Perles
  • , Malena Cohen-Cymberknoh
  • , Eitan Kerem
  • , David Shoseyov*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Hepatopulmonary syndrome (HPS) is a liver-induced lung disorder defined as a triad of liver disease, pulmonary vascular dilatation, and a defect in oxygenation. It can complicate chronic liver disease of any etiology, but is most commonly associated with portal hypertension. Severe liver disease with portal hypertension is present in 2% to 8% of patients with cystic fibrosis (CF), but to date, to our knowledge, only one patient with CF has been reported to suffer from HPS. Here, we describe two patients with CF diagnosed with HPS, one subsequent to unresolved hypoxemia and the other following screening for HPS performed in our center. We speculate that HPS is underdiagnosed in patients with CF because of their coexisting respiratory morbidity, and we advocate routine screening for every patient with CF who has liver disease and portal hypertension.

Original languageEnglish
Pages (from-to)e35-e38
JournalChest
Volume149
Issue number2
DOIs
StatePublished - Feb 2016
Externally publishedYes

Bibliographical note

Publisher Copyright:
Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Hypoxia
  • Intrapulmonary vascular shunt
  • Liver disease
  • Portal hypertension

Fingerprint

Dive into the research topics of 'Hepatopulmonary syndrome in patients with cystic fibrosis and liver disease'. Together they form a unique fingerprint.

Cite this